Compare CHGG & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHGG | ACET |
|---|---|---|
| Founded | 2005 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.4M | 111.9M |
| IPO Year | 2013 | N/A |
| Metric | CHGG | ACET |
|---|---|---|
| Price | $0.89 | $0.62 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 5 | 4 |
| Target Price | $1.42 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 3.0M | 1.8M |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $447,733,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.44 | $0.45 |
| 52 Week High | $2.73 | $1.19 |
| Indicator | CHGG | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 39.00 | 41.57 |
| Support Level | $0.87 | $0.58 |
| Resistance Level | $1.01 | $0.70 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 4.93 | 41.88 |
Chegg Inc is an American educational services company. The Chegg platform provides products and services to support learners with their academic course materials, as well as their career and personal skills development. The company's service and product offerings fall into two categories: Subscription Services, which encompasses Chegg Study Pack, Chegg Study, Chegg Writing, Chegg Math, and Busuu offerings that can be accessed internationally through the company's websites and on mobile devices, and Skills and Other, which encompasses skills, advertising services, print textbooks, and eTextbooks offerings.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.